Filing Flows › Vistagen Therapeutics (VTGN) › Next earnings date
Vistagen Therapeutics (VTGN) earnings on Nov 12, 2026: what to expect
Vistagen Therapeutics (VTGN) is expected to report earnings on Nov 12, 2026 (estimated), in 4 days, for the quarter ending Sep 30, 2026. Analysts expect EPS of −$0.38 (−$0.38 to −$0.37, 2 estimates) on revenue of $250K, against −$0.54 and $258K a year ago. It beat the EPS estimate in 50% of the quarters on record; Filing Flows' model gives it a 64% chance of beating next time.
What to watch
Last quarter (Q1 FY27) the lines that make up revenue grew like this; the report shows whether the trend holds:
Filing Flows' own estimate from the SEC figures — the same quarter last year times recent growth — is EPS −$0.54 on revenue of $661K, against the analysts' −$0.38.
The last report
Vistagen Therapeutics reported revenue of $1.5M for the first quarter fiscal 2027 (+505% Y/Y), net loss $13.0M. How it makes money → · Every quarter →
Vistagen Therapeutics' latest quarter
Vistagen Therapeutics, Q1 FY27: revenue $1.5M (+505% year over year), operating margin -904.3%, net loss $13.0M, operating cash flow −$14.7M. The chart follows the revenue to costs, profit and cash.
Questions
When does VTGN report earnings?
Vistagen Therapeutics is expected to report on Nov 12, 2026 (estimated).
What are analysts expecting from Vistagen Therapeutics?
EPS of −$0.38 and revenue of $250K for the quarter.
Does Vistagen Therapeutics usually beat earnings?
It beat the consensus EPS estimate in 50% of the quarters on record.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.